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Letters to the Editor
Improving Procedural Times
During Percutaneous Atrial
Septal Defect Closure
We read with interest the expedited review by Jones et al. (1)
which details multicenter experience with the Helex Septal
Occluder device (W. L. Gore and Associates, Flagstaff, Ari-
zona) for the percutaneous closure of secundum atrial septal
defects (ASD). The investigators report a favorable experience
with the device relative to surgical closure in terms of length of
hospital stay and duration of anesthesia, with equivalence in the
primary end point of the study, which was “clinical success.” At
Oxford we have used the Helex device for over 3 years for both
patent foramen ovale (PFO) and ASD closures with 2 dedicated
operators. Since June 2006 we have used the Helex device to
close secundum ASDs in 38 patients successfully with no
significant adverse events. A key point of difference is the
markedly lower procedural time and fluoroscopy time in our
cohort compared with the reported study (average fluoroscopic
time 7.4 vs. 28 min, respectively; total time under anesthesia
49.4 vs. 160 min, respectively). In fact, our low fluoroscopy
times have enabled us to close PFOs using the Helex device
rapidly and safely in pregnancy (2).
It is unclear why this difference is apparent. We now
routinely use intracardiac echocardiography (ICE) during the
procedure, which has resulted in a reduction in procedural time
by avoiding the need for general anesthesia, which is often
required if transesophageal echocardiography is used, and has
allowed same-day discharge of these patients. The proportion
of patients in the reported study that underwent the proce-
dure with adjunctive ICE is not reported, and whether this
is a factor in the disparity observed in both procedural and
fluoroscopy times is not known but could indeed play a role.
Certainly, our single-center dedicated-operator experience us-
ing ICE to close secundum ASDs with the Helex device has
yielded low procedural and fluoroscopy times with excellent
results and no significant adverse events. In centers using this
device, operator familiarity and ICE could help in optimizing
procedural times.
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Reply
We appreciate the interest by Drs. Bhindi and Ormerod who
comment favorably on our paper, “Results of the Multicenter
Pivotal Study of the Helex Septal Occluder for Percutaneous
Closure of Secundum Atrial Septal Defects,” recently published in
the Journal (1). They report their own successful experience with
the use of the Helex Septal Occluder in 38 patients with atrial
septal defect (ASD) at the John Radcliffe Hospital in Oxford,
United Kingdom. They go on to draw a distinction between the
procedural and fluoroscopic time in their own experience versus
what was reported in our paper. Furthermore, they speculate that
some of this difference could be due to their routine use of
intracardiac echocardiography (ICE) instead of transesophageal
echocardiography.
There are several factors that likely contributed to the
differences in procedural and fluoroscopic time reported in their
experience and our multicenter trial. Our pivotal trial repre-
sented some of the earliest human experience with this tech-
nique when best clinical practices were being first defined. All of
our subjects were being treated for ASD, and most of them were
children. Some of those ASDs proved to be relatively large for
this device design (18 to 20 mm). Occasionally, the investiga-
tors made several attempts with multiple devices to close these
larger defects. This additional effort accounted for the wide
range of fluoroscopy time reported in our series, 6 min to 148
min. This is why we chose to report the median fluoroscopy
time of 22 min rather than the mean time of 28 min, believing
it more accurately represented the experience of the majority
our subjects. Furthermore, a complete hemodynamic study was
a protocol requirement that took time to perform. Drs. Bhindi
and Ormerod do not comment on their use of defect balloon
sizing in selecting proper size device, a time-consuming but not
universally practiced technique. Balloon sizing in our study was
another protocol-specified step that could further account for
the time differences. Finally, the Helex delivery system available
in Europe for several years, version 1.5, is much simpler and
faster to use. The older 1.0 version used in our trial is still the
only approved delivery system available in the U.S.
We do agree with Drs. Bhindi and Ormerod that the routine
use of ICE, at the time unavailable for the vast majority of our
subjects, has the effect of significantly reducing anesthesia time and
improving patient comfort by eliminating the requirement for
general endotracheal anesthesia. The impact of the use of ICE on
fluoroscopy time, however, is less certain and more likely related to
the other factors stated. We believe the biggest drawback to the
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